Expert Interview
Exploring the potential market impact and clinical benefits of Blujepa (gepotidacin) as a novel treatment option for uncomplicated urinary tract infections (uUTIs) in light of the recent FDA Approval
Ticker(s): GSKInstitution: University of Miami Miller School of Medicine (Former)
- Voluntary Professor of Clinical Medicine at the University of Miami Miller School of Medicine with 40-year history of clinical care and research in Infectious Diseases and especially UTI in women
- Former Epidemic Intelligence Officer (EIS) and researcher in hospital associated infections at the Centers for Disease Control (CDC)
- Principal research focus has been to better understand the epidemiology, pathogenesis, treatment and prevention of UTI in women
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
